Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy with Aprepitant/Fosaprepitant in Patients with Colorectal Cancer Receiving Oxaliplatin-based chemotherapy
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2620869
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: For aprepitant therapy Aprepitant; 125 mg PO on day 1, 80 mg PO on days 2 to 3 5HT3-receptor antagonist; IV administration on day 1 Dexamethasone; 6.6 mg IV on day 1, 4 mg PO on days 2 to 3 For fosaprepitant therapy Fosaprepitant; 150 mg IV on day 1 5HT3-receptor antagonist; IV administration on day 1 Dexamethasone; 6.6 mg IV on day 1, 4 mg PO on day 2 and 8mg PO on day 3
5HT3-receptor antagonist; IV administration on day 1 Dexamethasone; 9.9 mg IV on day 1, 8 mg PO on days 2 to 3
Primary outcome(s): Proportion of patients with ‘No emesis"
Study Design: Parallel Randomized
创建时间：
2011-04-15
